600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.
Closed 12-10 15:00:00
28.32
+0.87
+3.17%
High28.80Low28.18Vol39.17M
Open28.45D1 Closing27.45Amplitude2.26%
Mkt Cap75.61BTradable Cap59.98BTotal Shares2.67B
T/O1.11BT/O Rate1.85%Tradable Shares2.12B
P/B1.57ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Shanghai Fosun Pharma Says Foscarnet Sodium Injection Of Unit Approved By NMPA
Reuters  ·  18:20
BRIEF-Shanghai Fosun Pharma Says Foscarnet Sodium Injection Of Unit Approved By NMPA
Shanghai Fosun Pharma - Foscarnet Sodium Injection of Unit Approved by Nmpa
THOMSON REUTERS  ·  18:19
Shanghai Fosun Pharma - Foscarnet Sodium Injection of Unit Approved by Nmpa
Capital Securities Maintains "Buy" Rating on Fosun Pharma (02196) with Target Price of HK$26.5
Stock News  ·  15:36
Capital Securities Maintains "Buy" Rating on Fosun Pharma (02196) with Target Price of HK$26.5
Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs. -- Barrons.com
Dow Jones  ·  00:50
Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs. -- Barrons.com
FOSUN PHARMA (600196.SH): HLX22 Combined with HLX87 Injection Receives Clinical Trial Approval
Stock News  ·  12-09 20:15
FOSUN PHARMA (600196.SH): HLX22 Combined with HLX87 Injection Receives Clinical Trial Approval
Fosun Pharma Subsidiary Yao Pharma Grants Pfizer Exclusive Global License for Oral GLP-1R Agonists
Reuters  ·  12-09 19:56
Fosun Pharma Subsidiary Yao Pharma Grants Pfizer Exclusive Global License for Oral GLP-1R Agonists
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter Into Exclusive Collaboration and License Agreement
THOMSON REUTERS  ·  12-09 19:55
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter Into Exclusive Collaboration and License Agreement
Fosun Pharmaceutical Says Unit to Receive Upfront Payment of $150 Mln
THOMSON REUTERS  ·  12-09 18:57
Fosun Pharmaceutical Says Unit to Receive Upfront Payment of $150 Mln
BRIEF-Fosun Pharmaceutical Says Unit Signs Licensing Agreement With Pfizer
Reuters  ·  12-09 18:57
BRIEF-Fosun Pharmaceutical Says Unit Signs Licensing Agreement With Pfizer
Fosun Pharmaceutical's Seven Drugs Included in China's Insurance Drug List
MT Newswires Live  ·  12-08 14:51
Fosun Pharmaceutical's Seven Drugs Included in China's Insurance Drug List
Fosun Pharma Gets Greenlight for Tumor Drug Trials
MT Newswires Live  ·  12-04
Fosun Pharma Gets Greenlight for Tumor Drug Trials
BRIEF-Shanghai Fosun Pharma's Unit Received Approval From NMPA For Clinical Trial Of Fxs887 Tablets
Reuters  ·  12-03
BRIEF-Shanghai Fosun Pharma's Unit Received Approval From NMPA For Clinical Trial Of Fxs887 Tablets
Shanghai Fosun Pharma - Unit Received Approval From Nmpa for Clinical Trial of Fxs887 Tablets
THOMSON REUTERS  ·  12-03
Shanghai Fosun Pharma - Unit Received Approval From Nmpa for Clinical Trial of Fxs887 Tablets
Fosun Pharmaceutical Gets Acceptance for Drug Registration Application for Denosumab Biosimilar
MT Newswires Live  ·  12-03
Fosun Pharmaceutical Gets Acceptance for Drug Registration Application for Denosumab Biosimilar
Fosun Pharmaceutical Gets Regulatory Acceptance for Anticoagulant Registration Application
MT Newswires Live  ·  12-03
Fosun Pharmaceutical Gets Regulatory Acceptance for Anticoagulant Registration Application
BRIEF-Shanghai Fosun Pharma Says Liu Yi Elected As Executive Director
Reuters  ·  12-02
BRIEF-Shanghai Fosun Pharma Says Liu Yi Elected As Executive Director
BRIEF-Shanghai Fosun Pharma Says Drug Application Of Heparin Sodium Injection Accepted By NMPA
Reuters  ·  12-02
BRIEF-Shanghai Fosun Pharma Says Drug Application Of Heparin Sodium Injection Accepted By NMPA
Shanghai Fosun Pharma - Drug Application of Heparin Sodium Injection Submitted by Unit Accepted by Nmpa
THOMSON REUTERS  ·  12-02
Shanghai Fosun Pharma - Drug Application of Heparin Sodium Injection Submitted by Unit Accepted by Nmpa
Fosun Pharma Subsidiary Wins Acceptance for Drug Registration Application
Reuters  ·  12-02
Fosun Pharma Subsidiary Wins Acceptance for Drug Registration Application
FOSUN PHARMA (02196): Liu Yi Elected as Executive Director
Stock News  ·  12-02
FOSUN PHARMA (02196): Liu Yi Elected as Executive Director

Introduction

Company Name.
上海复星医药(集团)股份有限公司
Industry:
医药制造业
Listing Date:
1998-08-07
Main Business:
　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
Issue price:
7.15